Ennature Bio Pharma Limited lists with Rs 246 crore revenue

Ennature Bio Pharma Limited listed on the National Stock Exchange of India and BSE Limited on 4 November 2026 after reporting Rs 246 crore of financial year 2026 (FY26) biopharma revenue, while identifying branded nutraceutical ingredients as its primary growth driver and targeting a portfolio of six to eight ingredients.

What did Ennature’s NSE and BSE listing announce?

Ennature announced that its equity shares listed on NSE and BSE on 4 November 2026, bringing its integrated natural-ingredients business to the public market. The company described its operating platform as three complementary businesses: plant-based pharmaceutical ingredients, biopolymers and nutraceuticals.

The listing announcement set out a strategy based on expanding science-backed botanical ingredients rather than disclosing an offer size, valuation, shareholding change or capital-raising amount. Ennature said its established active pharmaceutical ingredient (API) and biopolymer activities provide the base for an increased focus on branded nutraceutical ingredients with higher value-added positioning.

The business mix gives the API operation the largest role in sales, while nutraceuticals are the smallest of the three reported segments but the stated growth focus. The following FY26 sales composition was disclosed by Ennature.

The comparison shows that API sales represented 50 percentage points more of sales than nutraceuticals in FY26, while biopolymers trailed nutraceuticals by 1 percentage point. Ennature’s strategy therefore combines expansion of its largest established business with efforts to increase the contribution of branded ingredients in the 17% nutraceutical segment.

What financial base does Ennature report for FY26?

Ennature reported Rs 246 crore of FY26 net revenue, Rs 29 crore of earnings before interest, taxes, depreciation and amortisation (EBITDA), and a gross margin of 40.1% for its biopharma division. These are the financial figures cited in the 4 November 2026 listing announcement for the division underpinning the three operating segments.

The announcement did not provide prior-year revenue, EBITDA or margin figures, so it does not permit a year-on-year calculation of growth or margin movement. It does provide a segment comparison: the 67% API share was nearly four times the 17% nutraceutical share, whereas the 16% biopolymer business was slightly smaller than nutraceuticals by sales mix.

Exports were material across each reported segment in FY26, though their contribution differed. APIs derived 54% of segment revenue from exports, compared with 69% for biopolymers and 83% for nutraceuticals. Nutraceuticals therefore had the highest disclosed export proportion, 29 percentage points above APIs, while biopolymers were 15 percentage points above APIs.

Ennature did not separately disclose revenue or profit in rupees for each of the three segments, nor did it provide capital expenditure, order-book or pricing data. The filing instead ties the Rs 246 crore revenue base to operating priorities: one new API annually, higher-value biopolymer derivatives, and an expanded branded nutraceutical portfolio.

How will Ennature develop its API and biopolymer businesses?

Ennature plans to introduce one new API each year, increase its presence in regulated markets and strengthen its nicotine replacement therapy portfolio. Its existing API range includes thiocolchicoside, colchicine, nicotine and vinpocetine, and the company said the operation has been built over more than 15 years.

The API business serves more than 150 active customers in over 26 countries, with exports accounting for 54% of FY26 segment revenue. As APIs account for 67% of sales, this segment remains the company’s largest disclosed commercial base while the planned annual product additions are intended to extend that portfolio.

Ennature’s biopolymer segment accounted for 16% of FY26 sales and produces guar gum and speciality gums. These materials serve oil and gas, food and beverages, personal care, paints, textiles and supplements, giving the segment exposure to a broader end-market range than the API portfolio described in the announcement.

For biopolymers, Ennature’s stated priorities are specialised derivatives, dietary-fibre applications and a higher contribution from value-added products. The segment serves customers across 23 countries, and exports supplied 69% of its FY26 revenue, a higher export share than the API business’s 54%.

What is Ennature’s branded nutraceutical strategy?

Ennature aims to expand its branded nutraceutical range to six to eight ingredients, from a current portfolio of five flagship brands: Aspargize, Gingeren, Maxicuma®, Xanthogreen® and Berbisol™. The company said this 17%-of-sales segment is its primary growth driver and is moving beyond standardised botanical extracts.

The targeted branded ingredients are intended for women’s health, bone and joint health, eye health and metabolic health. Ennature said its differentiation approach relies on scientific research, proprietary technology and clinical validation, rather than simply adding botanical extracts to the portfolio.

The nutraceutical business has more than 90 active customers across over 19 countries, with exports making up 83% of FY26 revenue. Ennature plans to strengthen distribution in the United States, Europe and Asia, and to deepen relationships with leading nutraceutical customers as it increases the branded portfolio beyond five ingredients.

Two proprietary technology platforms, LIMAN™ and SCEMOD™, are intended to improve ingredient solubility and bio-absorption. Ennature reported nine patent filings, including five granted patents and four under review, alongside a research programme comprising 20 clinical trials; the filing did not specify trial outcomes, completion dates or the ingredients covered by each trial.

What manufacturing and international infrastructure supports the plan?

Ennature operates manufacturing facilities in Dehradun and Kashipur with disclosed capacities of 1,600 metric tonnes and 24,000 metric tonnes, respectively. The two sites therefore have a combined disclosed manufacturing capacity of 25,600 metric tonnes.

The facilities support supercritical fluid extraction, solvent and aqueous extraction, bio-fermentation and semi-formulation. Ennature also cited European Union good manufacturing practice certification, Certificates of Suitability, United States Food and Drug Administration certification, and NSF good manufacturing practice certification, although the announcement did not assign individual certifications to a specific site or product line.

Internationally, Ennature has a local United States office to support customer coverage and stocking capabilities. That presence aligns with the plan to expand nutraceutical distribution across the United States, Europe and Asia, while the existing API, biopolymer and nutraceutical segments already serve more than 26, 23 and 19 countries, respectively.

Conclusion

Ennature’s 4 November 2026 NSE and BSE listing accompanies a strategy that keeps its 67%-of-sales API business and 16%-of-sales biopolymer operation as operating foundations while prioritising branded nutraceuticals, which represented 17% of sales and generated an 83% export share in FY26. The stated financial base was Rs 246 crore of biopharma revenue, Rs 29 crore of EBITDA and a 40.1% gross margin.

The next disclosed milestones to watch are whether Ennature introduces the planned one new API annually and expands its branded nutraceutical range from five to six to eight ingredients. Progress in the 20-clinical-trial programme, the four patents under review, United States office coverage and distribution expansion in the United States, Europe and Asia will indicate how the announced growth plan is being implemented.